Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ludwig Enterprises Announces Launch of New Nutraceutical and Strategic Marketing Plan
Details : NuGenea is a nutraceutical formulated with 20 different ingredients which have been scientifically shown to help fight chronic inflammation, which is a causative factor in illnesses such as cancer, diabetes, COPD and heart disease.
Product Name : NuGenea
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Announces U.S. Launch of PKU GOLIKE
Details : PKU GOLIKE® - a next generation medical phenylalanine-free food product engineered with the patent protected, pharmaceutical grade Physiomimic™ technology for the dietary management of phenylketonuria (PKU).
Product Name : PKU GOLIKE
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amino Acids Mixture,Minerals,Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Relief Therapeutics
Deal Size : $72.2 million
Deal Type : Acquisition
Details : Acquisition further diversifies Relief's pipeline with both commercial products and clinical-stage programs and provides a commercial infrastructure foundation for future product launches.
Product Name : PKU Golike
Product Type : Other Small Molecule
Upfront Cash : $23.3 million
June 29, 2021
Lead Product(s) : Amino Acids Mixture,Minerals,Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Relief Therapeutics
Deal Size : $72.2 million
Deal Type : Acquisition